Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Chenghong Peng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5573-7873; OpenAlex author ID A5000295129. Sources: OpenAlex.

Their work

Papers
67 (first author 0, last author 19)
Trials
0
Grants
0
Labs led
1
Collaborators
109
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 4 papers · 2014: 3 papers · 2015: 3 papers · 2016: 5 papers · 2017: 6 papers · 2018: 4 papers · 2019: 7 papers · 2020: 4 papers · 2021: 12 papers · 2022: 8 papers · 2023: 7 papers · 2024: 1 paper · 2025: 1 paper

Papers 50 of 67

  1. Identification of a Novel Small Molecule STING Agonist Reshaping the Immunomicroenvironment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/ijbs.107837↗
  2. BHLHE40 Inhibits Ferroptosis in Pancreatic Cancer Cells via Upregulating SREBF1. Co-author DOI 10.1002/advs.202306298↗
  3. Long-term outcomes of standard versus extended lymphadenectomy in pancreatoduodenectomy for pancreatic ductal adenocarcinoma: A Chinese multi-center prospectiv… Co-author DOI 10.1016/j.jare.2022.09.011↗
  4. Schwann cells regulate tumor cells and cancer-associated fibroblasts in the pancreatic ductal adenocarcinoma microenvironment. Co-author DOI 10.1038/s41467-023-40314-w↗
  5. Specific human leukocyte antigen class I genotypes predict prognosis in resected pancreatic adenocarcinoma: a retrospective cohort study. Co-author DOI 10.1097/js9.0000000000000264↗
  6. Retraction Note: The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA. Co-author DOI 10.1186/s13045-023-01506-5↗
  7. The Impact of Additional Para-aortic Dissection During Pancreaticoduodenectomy for Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-12700-z↗
  8. LINC01137 facilitates pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis Co-author DOI 10.21203/rs.3.rs-2411868/v1↗
  9. Comprehensive machine learning-generated classifier identifies pro-metastatic characteristics and predicts individual treatment in pancreatic cancer: A multice… Co-author DOI 10.7150/thno.84978↗
  10. The impact of Omicron pandemic and COVID-19 vaccination on the pancreatic adenocarcinoma patients. Co-author DOI 10.1002/aac2.12056↗
  11. The CTCF/LncRNA-PACERR complex recruits E1A binding protein p300 to induce pro-tumour macrophages in pancreatic ductal adenocarcinoma via directly regulating P… Co-author DOI 10.1002/ctm2.654↗
  12. Robotic versus open pancreaticoduodenectomy with vascular resection for pancreatic ductal adenocarcinoma: surgical and oncological outcomes from pilot experien… Co-author DOI 10.1007/s00423-021-02364-w↗
  13. Oncological outcomes of robotic pancreatectomy in patients with pancreatic cancer who receive adjuvant chemotherapy: A propensity score-matched retrospective c… Co-author DOI 10.1016/j.ijsu.2022.106801↗
  14. The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA. Co-author DOI 10.1186/s13045-022-01338-9↗
  15. Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1. Co-author DOI 10.1186/s13045-022-01348-7↗
  16. LINC01137 involvement in pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis Co-author DOI 10.21203/rs.3.rs-1516835/v1↗
  17. LINC01137 facilitate pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis Last author DOI 10.21203/rs.3.rs-2065916/v1↗
  18. Oncological outcomes of robotic-assisted versus open pancreatoduodenectomy for pancreatic ductal adenocarcinoma: a propensity score-matched analysis. Co-author DOI 10.1007/s00464-020-07791-2↗
  19. Identification of copy number variation-driven molecular subtypes informative for prognosis and treatment in pancreatic adenocarcinoma of a Chinese cohort. Co-author DOI 10.1016/j.ebiom.2021.103716↗
  20. Original study: The rescue staging for pancreatic ductal adenocarcinoma with inadequate examined lymph nodes. Co-author DOI 10.1016/j.pan.2021.02.010↗
  21. Oncogene APOL1 promotes proliferation and inhibits apoptosis via activating NOTCH1 signaling pathway in pancreatic cancer. Co-author DOI 10.1038/s41419-021-03985-1↗
  22. Positive feedback between lncRNA FLVCR1-AS1 and KLF10 may inhibit pancreatic cancer progression via the PTEN/AKT pathway. Co-author DOI 10.1186/s13046-021-02097-0↗
  23. A Novel DNA Replication-Related Signature Predicting Recurrence After R0 Resection of Pancreatic Ductal Adenocarcinoma: Prognostic Value and Clinical Implicati… Last author DOI 10.3389/fcell.2021.619549↗
  24. An EMT-Related Gene Signature for Predicting Response to Adjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3389/fcell.2021.665161↗
  25. Immunity-Related Gene Signature Identifies Subtypes Benefitting From Adjuvant Chemotherapy or Potentially Responding to PD1/PD-L1 Blockage in Pancreatic Cancer. Co-author DOI 10.3389/fcell.2021.682261↗
  26. A Novel Ferroptosis-Related Gene Signature Predicts Recurrence in Patients With Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3389/fmolb.2021.650264↗
  27. Transcriptomic Profiling Identifies DCBLD2 as a Diagnostic and Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fmolb.2021.659168↗
  28. Development and Validation of a 7-Gene Prognostic Signature to Improve Survival Prediction in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3389/fmolb.2021.676291↗
  29. A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.634881↗
  30. Tumor copy number instability is a significant predictor for late recurrence after radical surgery of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.3425↗
  31. Surgical resection of metastatic pancreatic cancer: is it worth it?-a 15-year experience at a single Chinese center. Last author DOI 10.21037/jgo.2020.03.02↗
  32. Serum tRNA-derived small RNAs as potential novel diagnostic biomarkers for Pancreatic Ductal Adenocarcinoma Co-author DOI 10.21203/rs.3.rs-63978/v1↗
  33. The Necessity of Dissection of No. 14 Lymph Nodes to Patients With Pancreatic Ductal Adenocarcinoma Based on the Embryonic Development of the Head of the Pancr… Co-author DOI 10.3389/fonc.2020.01343↗
  34. Perineural invasion is related to p38 mitogen-activated protein kinase pathway activation and promotes tumor growth and chemoresistance in pancreatic cancer. Co-author DOI 10.1002/jcb.28457↗
  35. Silencing of long noncoding RNA LINC00958 prevents tumor initiation of pancreatic cancer by acting as a sponge of microRNA-330-5p to down-regulate PAX8. Co-author DOI 10.1016/j.canlet.2018.12.017↗
  36. Corrigendum to "GFRα2 prompts cell growth and chemoresistance through down-regulating tumor suppressor gene PTEN via Mir-17-5p in pancreatic cancer" [Cancer Le… Last author DOI 10.1016/j.canlet.2019.03.031↗
  37. Should a standard lymphadenectomy include the No. 9 lymph nodes for body and tail pancreatic ductal adenocarcinoma? Co-author DOI 10.1016/j.pan.2019.03.005↗
  38. An allosteric PGAM1 inhibitor effectively suppresses pancreatic ductal adenocarcinoma. Co-author DOI 10.1073/pnas.1914557116↗
  39. RER1 enhances carcinogenesis and stemness of pancreatic cancer under hypoxic environment. Co-author DOI 10.1186/s13046-018-0986-x↗
  40. A new enhanced recovery after surgery pathway for left-sided pancreatic cancer patients after distal pancreatectomy. Last author DOI 10.21037/tcr.2019.10.26↗
  41. CQ sensitizes human pancreatic cancer cells to gemcitabine through the lysosomal apoptotic pathway via reactive oxygen species. Co-author DOI 10.1002/1878-0261.12179↗
  42. CUL4B promotes metastasis and proliferation in pancreatic cancer cells by inducing epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway. Last author DOI 10.1002/jcb.26643↗
  43. MiR-17-5p enhances pancreatic cancer proliferation by altering cell cycle profiles via disruption of RBL2/E2F4-repressing complexes. Co-author DOI 10.1016/j.canlet.2017.09.044↗
  44. Melittin-induced long non-coding RNA NONHSAT105177 inhibits proliferation and migration of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-018-0965-3↗
  45. lncRNA MEG3 had anti-cancer effects to suppress pancreatic cancer activity. Last author DOI 10.1016/j.biopha.2017.02.041↗
  46. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2017.04.012↗
  47. The over expression of long non-coding RNA ANRIL promotes epithelial-mesenchymal transition by activating the ATM-E2F1 signaling pathway in pancreatic cancer: … Co-author DOI 10.1016/j.ijbiomac.2017.03.123↗
  48. Long noncoding RNA NORAD, a novel competing endogenous RNA, enhances the hypoxia-induced epithelial-mesenchymal transition to promote metastasis in pancreatic … Co-author DOI 10.1186/s12943-017-0738-0↗
  49. Integrated expression profiles analysis reveals novel predictive biomarker in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.16732↗
  50. The effects of miRNA-1180 on suppression of pancreatic cancer. Last author PMID 28670370↗

Closest collaborators

The 25 strongest of 109 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Baiyong Shen · 45 shared papers, 2012–2024 · strength 4.15
  2. Xiaxing Deng · 27 shared papers, 2013–2023 · strength 2.84
  3. Hao Chen · 25 shared papers, 2013–2022 · strength 2.02
  4. Lingxi Jiang · 11 shared papers, 2020–2025 · strength 1.56
  5. Zengyu Feng · 10 shared papers, 2021–2023 · strength 1.50
  6. Kexian Li · 10 shared papers, 2021–2023 · strength 1.50
  7. Jiabin Jin · 13 shared papers, 2013–2023 · strength 1.19
  8. Yizhi Cao · 8 shared papers, 2022–2025 · strength 1.19
  9. Xiaxing Deng · 12 shared papers, 2013–2024 · strength 1.09
  10. Hao Chen · 8 shared papers, 2017–2024 · strength 1.06
  11. Chenlei Wen · 11 shared papers, 2016–2024 · strength 1.05
  12. Dongfeng Cheng · 9 shared papers, 2017–2024 · strength 0.94
  13. Baiyong Shen · 7 shared papers, 2016–2025 · strength 0.92
  14. Jiewei Lin · 7 shared papers, 2019–2023 · strength 0.92
  15. Weishen Wang · 7 shared papers, 2017–2024 · strength 0.88
  16. Jiancheng Wang · 7 shared papers, 2020–2023 · strength 0.88
  17. Qian Zhan · 13 shared papers, 2013–2021 · strength 0.87
  18. Kai Qin · 6 shared papers, 2022–2023 · strength 0.85
  19. Xiongxiong Lu · 12 shared papers, 2013–2023 · strength 0.81
  20. Shuyu Zhai · 5 shared papers, 2021–2025 · strength 0.80
  21. Yulian Wu · 5 shared papers, 2021 · strength 0.79
  22. Yuanchi Weng · 6 shared papers, 2015–2023 · strength 0.78
  23. Lijie Han · 5 shared papers, 2022–2024 · strength 0.69
  24. Youwei Zhu · 6 shared papers, 2018–2024 · strength 0.66
  25. Yongsheng Jiang · 4 shared papers, 2022–2024 · strength 0.56

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.